Chardan analyst Gbola Amusa raised his price target for MeiraGTx Holdings (MGTX) to $40 from $30 following Johnson & Johnson’s equity stake in the company. MeiraGTx , a top pick for 2019 at Chardan, announced a strategic collaboration on inherited retinal diseases with J&J’s Janssen Pharmaceuticals and an $80M private placement, with the investment arm of J&J taking a $40M stake, Amusa tells investors in a research note. The news represents the third announced collaboration or investment by a J&J vehicle in MeiraGTx, the analyst points out. This may signal potential takeover interest by J&J longer term and suggests the pharma giant sees significant value in the inherited retinal diseases market opportunities, contends Amusa. He keeps a Buy rating on MeiraGTx.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.